Topical therapy in the treatment of actinic keratosis and basal cell carcinoma

Cutis

Volumn 79, Issue 4 SUPPL., 2007, Pages 18-28

  Newman, Marissa D ^a   Weinberg, Jeffrey M ^b,c,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

^d College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; RETINOID; TUBULIN MODULATOR;

BASAL CELL CARCINOMA; HUMAN; INTRADERMAL DRUG ADMINISTRATION; KERATOSIS; REVIEW; SKIN TUMOR;

ADMINISTRATION, CUTANEOUS; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CYCLOOXYGENASE INHIBITORS; HUMANS; KERATOSIS; RETINOIDS; SKIN NEOPLASMS; TUBULIN MODULATORS;

EID: 34248324440     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Anwar J, Wrone DA, Kimyai-Asadi A, et al. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol. 2004;22:189-196.
2. Ulrich C, Busch JO, Meyer T, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol. 2006;155:451-455.
3. Yantsos VA, Conrad N, Zabawski E, et al. Incipient intraepithelial cutaneous squamous cell carcinoma: a proposal for reclassifying and grading solar (actinic) keratoses. Semin Cutan Med Surg. 1999;18:3-14.
4. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1998;1:795-797.
5. Berman B, Bienstock L, Kuritzky L, et al; Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments, recommendations from a consensus panel. J Fam Pract. 2006;55(suppl):1-8.
6. Cockerell CJ, Wharton JR. New histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma). J Drugs Dermatol. 2005;4:462-467.
7. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51:547-555.
8. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721.
9. Loven K, Stein L, Furst K, et al. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24:990-1000.
10. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(suppl 2):22-29.
11. Wolf JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dematol. 2001;40:709-713.
12. Rivers JK, Ariette K, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dematol. 2002;146:94-100.
13. Grimaitre M, Etienne A, Fathi M, et al. Topical colchicine therapy for actinic keratoses. Dermatology. 2000;200: 346-348.
14. Akar A, Bulent T, Erbil H, et al. Efficacy and safety assessment of 0.5% and 1% colchicine cream in the treatment of actinic keratoses. J Dermatolog Treat. 2001;12: 199-203.
15. Kligman A, Thorne E. Topical therapy of actinic keratoses with tretinoin. In: Marks R, ed. Retinoids in Cutaneous Malignancy. Oxford, England: Blackwell Scientific Publications; 1991:66-73.
16. Alirezai M, Dupuy P, Amblard P, et al. Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dematol. 1994;30:447-451.
17. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dematol. 2001;45:528-536.
18. Gallagher RP, Ma B, McLean DI, et al. Trends in basal cell carcinoma, squamous cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol 1990;23:413-421.
19. Scrivener Y, Grosshans E, Cribier B. Variations of basal cell carcinomas according to gender, age, location and histopathological subtype. Br J Dermatol. 2002;147: 41-47.
20. Walling HW, Fosko SW, Geraminejad PA, et al. Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev. 2004;23:389-402.
21. Silverman MK, Kopf AW, Grin CM, et al. Recurrence rates of treated basal cell carcinomas, part 2: curettage-electrodesiccation. J Dermatol Surg Oncol. 1991;17: 720-726.
22. Madani S, Huilgol SC, Carruthers A. Unplanned incomplete Mohs micrographie surgery. J Am Acad Dermatol. 2000;42:814-819.
23. Edens BL, Bartlow GA, Haghighi P, et al. Effectiveness of curettage and electrodesiccation in the removal of basal cell carcinoma. J Am Acad Dermatol. 1983;9:383-388.
24. Rowe DE, Carroll RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol. 1989;15:315-328.
25. Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional Interferon. J Am Acad Dermatol. 1986;15:437-443.
26. Meyer T, Nindl I, Schmook T, et al. Induction of apoptosis by toll-like receptor-7 agonist in tissue cultures. Br J Dermatol. 2003;149:9-14.
27. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002;138:1498-1502.
28. Persaud AN, Shamuelova E, Sherer D, et al. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol. 2002;47:553-556.
29. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol. 2002;47:571-577.
30. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel group, vehicle-controlled trials. Arch Dermatol. 2005;141:467-473.
31. Falagas ME, Angelousi AC, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006;55:537-538.
32. Lee PK, Harwell WB, Loven KH, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg. 2005;31:659-664.
33. Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126:1251-1255.
34. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999;41:1002-1007.
35. Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week does-response trial. J Am Acad Dermatol. 2001;44:807-813.
36. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47:390-398.
37. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138:1165-1171.
38. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227-1236.
39. Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50:722-733.
40. Thissen MR, Kuijpers DI, Krekels GA. Local immune modulator (imiquimod 5% cream) as adjuvant treatment after incomplete Mohs micrographic surgery for large, mixed type basal cell carcinoma: a report of 3 cases. J Drugs Dermatol. 2006;5:461-464.
41. Wu J, Oh C, Strutton G, et al. An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol. 2006;47:46-48.
42. Spencer JM. Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. Dermatol Surg. 2006;32:63-69.
43. Berman B, Frankel S, Villa AM, et al. Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. Dermatol Surg. 2005;31:1399-1403.
44. Kligman A, Zhen Y, Sadiq I, et al. Imiquimod 5% cream reverses histologic changes and improved appearance of photoaged facial skin. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7, 2006; San Francisco, Calif.